The Clinical Evidence Base for Epigenetic Medicine

Where Biohacking Meets Cell Intelligence — XELGEN at Biohackers World LA 2026

Nearly 2,000 biohackers, longevity researchers, and clinicians gathered in Los Angeles for Biohackers World 2026 — and the conversation around exosome and stem cell therapy has never been more urgent. XELGEN's co-founder and Chief Growth Officer were there, and what they witnessed confirmed everything we are building toward: the market is ready for precision cellular intelligence.

Biohackers World LA was a defining moment for XELGEN in the United States. The passion in that room — from clinicians asking hard questions about exosome potency, to biohackers demanding data behind their therapies — is exactly the energy that drives our work. We are now actively partnering with leading clinics across Los Angeles and San Francisco, bringing the XELGEN Cell Intelligence Platform to the clinicians who are shaping the future of regenerative medicine.

XELGEN at the American Academy for Stem Cell Physicians — Miami 2026

XELGEN attended the AASCP Conference in Miami — one of the most important gatherings of stem cell clinicians in the United States. The consensus was clear: stem cell medicine is evolving faster than the clinical frameworks supporting it. The missing piece? Cellular intelligence.

The XELGEN Cell Intelligence Platform has officially landed in the United States. Following AASCP Miami, we are now in active discussions with stem cell clinics across the country to deploy precision epigenetic intelligence in real clinical settings. Next stop: Los Angeles.

XELGENがAASCPカンファレンス — マイアミ 2026に参加 🇯🇵

XELGENは、米国で最も重要な幹細胞医療の専門家・研究者が集うAASCPマイアミ大会に参加しました。コンセンサスは明確でした。幹細胞医療は、それを支える臨床フレームワークよりも速く進化しています。欠けているピース、それがセルインテリジェンスです。

XELGENセルインテリジェンス・プラットフォームが米国に正式上陸。AASCPマイアミ参加を経て、全米の幹細胞クリニックと積極的な協議を進めています。次の目的地：ロサンゼルス。

Combining Biology and AI To Advance Cell Therapy

One of the most enduring goals in regenerative medicine is deceptively simple: replace a person's damaged or dying cells with healthy new ones grown in the laboratory. A Harvard Medical School spinout is now combining deep biological insight with AI to make that goal a clinical reality — accelerating the path from stem cell science to scalable therapy.

This is exactly the convergence XELGEN is built for. Deep cellular knowledge — decoded at the epigenomic level — is the foundation of true cell intelligence. As AI begins to read the language of cells, XELGEN's genome-wide DNA methylation platform provides the biological ground truth that makes those models clinically meaningful. The future of regenerative medicine is not just smarter algorithms; it is algorithms trained on richer cellular data.

Epigenetics and the Exposome: A New Era of Disease Prevention

NIEHS Director Rick Woychik speaks with Harvard's Andrea Baccarelli about how the epigenome acts as a molecular fingerprint of every environmental exposure we encounter — from air pollution to diet to stress — and how DNA methylation patterns can reveal past exposures and predict disease risk years before symptoms appear.

This is the science that underpins everything XELGEN does. The exposome leaves its marks in DNA methylation — and XELGEN's genome-wide 850K CpG platform reads those marks with clinical precision. Every patient we screen carries an epigenomic record of their lifetime exposures. Our role is to decode that record, quantify biological age acceleration, and give clinicians the intelligence to intervene before disease takes hold.

Systemic Epigenetic Dysregulation as a Driver of Ageing and a Therapeutic Target

Harvard's Vadim Gladyshev proposes a landmark four-pillar framework in Nature Reviews Molecular Cell Biology: ageing is driven by systems-level failure of epigenetic fidelity — nuclear architecture deterioration, epigenetic memory collapse, histone variant drift, and AP-1 transcriptional hijacking — not merely by isolated methylation changes.

This is the theoretical foundation that gives XELGEN's 850K CpG platform its clinical power. When Gladyshev argues that ageing reflects 'collapse of coordinated chromatin regulation,' he is describing exactly what XELGEN measures at genome-wide resolution. Our methylation screen does not just report a biological age number — it reads the fidelity of the entire epigenetic control system across 850,000 CpG sites, giving clinicians a direct window into which of these four failure modes is already active in their patient.

The Exposome of Brain Aging Across 34 Countries

The largest global study of its kind — 18,701 individuals across 34 countries — shows that 73 environmental factors (air pollution, climate variability, green space, water quality, socioeconomic inequality, democratic stability) explain up to 15× more variance in brain aging than any single exposure alone. Crucially, the effects are syndemic and nonlinear: interactions across domains amplify biological impact far beyond what any single-factor model can detect.

This landmark finding is the scientific case for what XELGEN does. Single biomarkers, single exposures, single interventions — none of them capture the true biology of aging. XELGEN's 850K CpG methylation platform reads the genome-wide fingerprint of every accumulated exposure simultaneously, mapping how air quality, stress, diet, inflammation, and social environment have interacted to accelerate or protect biological age. When Legaz et al. show that multi-factor interaction explains 15× more variance than any single factor, they are describing exactly why XELGEN's multi-dimensional epigenomic screen is the clinical tool that precision medicine has been waiting for.

Aging Is Medicine's Biggest Blind Spot

ARPA-H's PROSPR program is launching the first Phase 3 clinical trial targeting aging itself — not a single disease — using FDA-approved drugs and a validated biomarker score designed to predict 20-year health outcomes. A $38 trillion opportunity is finally getting the clinical infrastructure it deserves.

ARPA-H's mandate to build validated aging biomarker scores and accessible home testing kits is a direct validation of XELGEN's clinical thesis. Our genome-wide DNA methylation platform already delivers the multi-system biological age intelligence that PROSPR is working to standardise — positioning XELGEN as the epigenetic layer that longevity medicine needs right now, not in 2031.

Epigenetic Patterns, Accelerated Biological Aging & Epigenetic Drift Detected 6 Months Following COVID-19 Infection

A genome-wide DNA methylation study of 96 post-COVID-19 patients found significant epigenetic age acceleration via Horvath's clock, 42 dysregulated CpG sites, and a substantial increase in stochastic epigenetic mutations — pointing to lasting biological damage across immune, vascular, and metabolic pathways, regardless of initial infection severity.

Biological ageing is not solely a function of time — it is actively shaped by conditions like COVID-19, which can accelerate epigenetic clocks and trigger lasting drift across immune, vascular, and metabolic pathways. XELGEN's genome-wide DNA methylation platform provides the most comprehensive and personalised epigenetic screening available, identifying current biological age acceleration and early signals of future risk before they manifest as disease.

The Race to Measure Aging — And Why It Matters

Scientists are racing to develop reliable biological age tests — and the results could reshape how we think about health, disease, and longevity. DNA methylation clocks are emerging as the most validated approach.

This TIME feature validates the clinical demand for epigenetic age measurement. XELGEN's genome-wide DNA methylation platform — built on Illumina EPIC arrays — delivers exactly the validated, physician-grade biological age insights the field is calling for.

With FDA Go-Ahead, a China Biotech Notches a First in Cell Therapy Testing

The FDA has cleared Shanghai-based Unixell to begin human studies of an allogeneic, stem cell-derived therapy targeting focal epilepsy — marking a new frontier for cell therapy indications globally.

Stem cell therapies for diverse disease indications are set to explode. What the field critically needs is XELGEN's Cell Intelligence platform to ensure cellular changes are continuously monitored, validated, and clinically documented throughout treatment.

FDA Greenlights Life Biosciences' Gene Therapy Study to Rewind the Age of Cells

In a major test for the longevity field, the FDA has cleared Life Biosciences to study a gene therapy designed to achieve a 'near total reset' of cellular age — co-founded by Harvard's David Sinclair.

Advancements in cell and gene therapy are pushing the boundaries of what's biologically possible. Yet there is a critical gap: the lack of standardized monitoring systems. XELGEN's Cell Intelligence platform provides exactly the epigenetic tracking infrastructure needed to document and validate these cellular age changes in real time.

3 New Venture Funds Collect Nearly $1B for Biotech in US & EU

A16z, BioNTech/Penn, and Servier Ventures have collectively raised nearly $1 billion in new biotech-focused funds, signaling strong investor conviction in next-generation life sciences platforms.

The surge in biotech venture capital reflects growing investor confidence in precision medicine platforms. XELGEN is positioned at the intersection of epigenomics, regenerative medicine, and clinical diagnostics — exactly the convergence point that top-tier funds are actively seeking to back.

NY Giants Team Doctor: Clinics Offering 'Miracle Injections' Are Selling False Hope

The head team physician for the New York Giants warns that regenerative medicine marketing has outpaced the science — and that unregulated stem cell clinics are putting patients at serious risk.

This is precisely why objective, validated cell therapy screening is essential. XELGEN's Cell Intelligence platform provides the epigenetic monitoring infrastructure that ensures regenerative therapies are not only administered — but rigorously tracked, validated, and proven effective for each individual patient.